Thermo Fisher Scientific Inc. to Issue Quarterly Dividend of $0.43 (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO) declared a quarterly dividend on Wednesday, May 21st, RTT News reports. Investors of record on Friday, June 13th will be given a dividend of 0.43 per share by the medical research company on Tuesday, July 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%.

Thermo Fisher Scientific has raised its dividend by an average of 14.5% per year over the last three years and has raised its dividend every year for the last 8 years. Thermo Fisher Scientific has a payout ratio of 7.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Thermo Fisher Scientific to earn $25.56 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 6.7%.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $397.89 on Thursday. The firm has a fifty day simple moving average of $447.48 and a two-hundred day simple moving average of $507.46. Thermo Fisher Scientific has a twelve month low of $390.50 and a twelve month high of $627.88. The company has a market capitalization of $150.20 billion, a PE ratio of 24.07, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 EPS. Research analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This trade represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock worth $7,305,942. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 491 shares of the medical research company’s stock after purchasing an additional 20 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on TMO shares. Citigroup lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Raymond James restated an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Finally, Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.